rPeptide

Executive Summary

rPeptide is a US-based biotechnology company founded in 2002 that specializes in manufacturing high-quality recombinant peptides, proteins, antibodies, and preformed fibrils for academic and industry research. The company serves as a critical reagent supplier with a strong focus on neurodegenerative diseases such as Alzheimer's and Parkinson's, offering both catalog products and extensive custom services including protein expression, purification, and isotopic labeling. As a private entity with no disclosed funding or valuation, rPeptide operates in a niche but essential segment of the life science tools market. The company's long-standing presence and specialized expertise position it as a reliable partner for researchers studying protein aggregation and misfolding. However, its limited scale and lack of publicly available financial data constrain growth visibility. Over the next 12-18 months, rPeptide may benefit from increasing R&D investment in neurodegenerative disease therapeutics and the potential launch of novel antibodies targeting new amyloid or tau species. The company's ability to expand its custom service offerings and secure collaborations with larger biopharma could drive revenue growth, though competition from major reagent suppliers remains a risk.

Upcoming Catalysts (preview)

• Q4 2026Launch of novel antibodies for emerging Alzheimer's targets (e.g., phospho-tau, alpha-synuclein strains)60% success
• H1 2027Partnership or contract with pharmaceutical company for custom protein production services45% success
• Q2 2027Introduction of preformed fibril kits for Parkinson's disease research70% success